Valsartan Sacubitril: Has our PARADIGM shifted?

Patients with heart failure with preserved ejection fraction (HFpEF) suffer from poor survival, high hospitalisations rate and long-term mortality. HFpEF patients are often overlooked as compared to the more well-known HFrEF where the famous “fantastic four” are now well-known as disease-modifying therapies. The plethora of evidence-based studies have time and again proven their value in the modification of the untoward outcomes in the latter. A recent ARNI trial has shown potential benefits of valsartan sacubitril on patients with HFpEF. Does that change the paradigm of how HFpEF should now be treated? Let us explore how we could apply the trial findings into our real-world clinical practice.

This webinar is the fourth in a series of six webinars from the ISCP focusing on the A to Z of CV Pharmacotherapy. Led by moderators Janice Wong (Malaysia) and Doreen Tan (Singapore), it includes a speaker presentation from Giuseppe Rosano (UK) and a discussion from panellists Richard Henry Tiongco (Philippines) and Rungroj Krittayphong (Thailand) that will examine the potential use of this agent in HFpEF population, through consideration of real-world examples, live discussions and audience Q&A.

This live webinar is EBAC accredited. 1 CME credit will be granted upon confirmation of successful attendance.

This is an independent activity run by the International Society of Cardiovascular Pharmacotherapy (ISCP). The ISCP has been provided support to develop this webinar by Novartis Singapore through an unrestricted educational grant. The supporter has had no influence on the content of the programme or provided any funding to Radcliffe Cardiology.